Former Karnataka chief ministers H D Kumaraswamy and Dharam Singh could be next to face corruption charges, threatening to complete the political triangle over graft in the state with BJP's B S Yeddyurappa already facing a probe for illegality in grant of mining leases and land scams. The Lok Sabha secretariat has turned down a request from a private individual seeking sanction for prosecution against former PM H D Deve Gowda's...

Looking closer at the Ambedkar cartoon and the power play in it We have examined a lot of politics and history around the Ambedkar cartoon but left the most important part unexamined — the very cartoon that created such a furore in Parliament. By assuming that the meaning of the cartoon is wholly dependent on one context, we have denied the work of art whatever autonomy of meaning it could have....

-The Indian Express Drug regulation is a mess. Everyone who propped up this irresponsible system is to blame Last week, a parliamentary standing committee on health delivered a thoroughly damaging report on the state of drug regulation in India, and the collusion between the regulator, industry and the medical profession that puts patients last. Over 118 pages, it said that the Drug Controller General of India (DCGI) and the Drug Standards Control...

Muslim women may finally get their due share in family inheritance. The long standing demand of the All India Muslim Personal Law Board for a suitable amendment in the UP Zamindari Abolition and Land Reform Act 1950 to bring it at par with the Shariat is likely to get an official nod soon. After AIMPLB reasserted its stance last month, the state government is considering the option to push through...

German drugmaker Bayer AG has demanded the withdrawal of the country's first compulsory licence given to Natco Pharma, arguing that a three-fourth reduction in the price of the anti-cancer drug by another Indian firm has made the permit redundant and its patent itself is vulnerable to being revoked. In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original...